Navigation Links
Predicting The Risk Of Osteoarthritis

Acetabular dysplasia is a developmental condition, often present at birth. It is marked by a shallow hip pocket and makes the hip unstable. In some extreme cases, it can make the hip prone to dislocation.// A new study reveals the condition acetabular dysplasia is a strong independent indicator for the development of osteoarthritis (OA) of the hip.

Osteoarthritis of the hip is one of the leading causes of disability among the elderly. In addition to severe acetabular dysplasisa, its development is associated with multiple factors, including genes, age, gender, hormones, and body mass index. Results of a recent study has shown that the condition acetabular dysplasia is a strong independent indicator for the development of osteoarthritis (OA) of the hip.

For the study researchers studied 835 seniors. Over a follow-up period averaging six years, participants were examined through radiographs for definite signs of hip OA. It was observed that those with acetabular dysplasia had about a four-times increased risk for OA of the hip and more women than men with acetabular dysplasia had severe hip OA.

Thus in conclusion researchers say acetabular dysplasia is a strong, independent indicator for the development of hip OA.
'"/>




Page: 1

Related medicine news :

1. Predicting The Risk Of Preeclampsia During Pregnancy
2. Predicting The Risk Of A Heart Attack
3. Predicting Severity Of Appendicitis With Computed Tomography
4. Predicting The Risk Of Breast Cancer In The Future
5. Predicting Breast Cancer Recurrence By Understanding Gene Signature
6. Researchers Find Mix of Biomarkers Predicting Mortality
7. Biomarkers Predicting Mortality Found Using Statistical Technique
8. HIV RNA Level Seen As Little Value In Predicting Treatment
9. Predicting the Dynamics of Clotting in Human Blood
10. Follicle Count Test as Good as Hormone Tests in Predicting Ovarian Response
11. New device for discerning Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/21/2017)... ... July 21, 2017 , ... Fresh Wave® IAQ today announced the launch ... for colleges and universities at the APPA 2017 Annual Conference and Exhibition ... tobacco smoke odors without the use of harsh chemicals, Fresh Wave IAQ Smoke Away ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... The Margarian ... falsely advertising the contents of its ginger ale for allegedly containing no ginger. Dr. ... Dr. Pepper Snapple Group, Inc., plaintiff Gegham Margaryan alleges Canada Dry Ginger Ale claims ...
(Date:7/21/2017)... ... 21, 2017 , ... “Kids aren't born knowing how to regulate their emotions ... Tucker, Founder of St. Louis-based positive education company Generation Mindful. To help with that ... July 21st. , The kit uses colorful, engaging and educational illustrations and games ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... ligament (ACL) offer patients improved quality of life five years after injury, according ... Annual Meeting in Toronto, Ontario, Canada. The study followed patients for five ...
(Date:7/20/2017)... Boston, MA (PRWEB) , ... July 20, 2017 ... ... aggressive form of blood and bone marrow cancer that progresses rapidly without treatment. ... often recommended to reduce the chance of reoccurrence and relapse. With such ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... 13, 2017  Centurion Medical Products, a leader in medical product ... fecal impaction removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part ... alleviate patient pain while preventing unneeded emergency department admission due to ...
(Date:7/11/2017)... IRVINE, Calif. , July 11, 2017 Zymo Research Corp., ... new service that can quantify biological aging in a precise manner using ... Dr. Steve Horvath , a professor of human genetics and biostatistics ... Fielding School of Public Health , Zymo Research,s proprietary DNAge ™ ... loci. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: